2018
Heart Failure After Ischemic Stroke or Transient Ischemic Attack in Insulin-Resistant Patients Without Diabetes Mellitus Treated With Pioglitazone
Young LH, Viscoli CM, Schwartz GG, Inzucchi SE, Curtis JP, Gorman MJ, Furie KL, Conwit R, Spatz E, Lovejoy A, Abbott JD, Jacoby DL, Kolansky DM, Ling FS, Pfau SE, Kernan WN. Heart Failure After Ischemic Stroke or Transient Ischemic Attack in Insulin-Resistant Patients Without Diabetes Mellitus Treated With Pioglitazone. Circulation 2018, 138: 1210-1220. PMID: 29934374, PMCID: PMC6202153, DOI: 10.1161/circulationaha.118.034763.Peer-Reviewed Original ResearchConceptsRisk of HFTransient ischemic attackEffect of pioglitazoneHF riskHeart failureInsulin-resistant patientsMyocardial infarctionIschemic attackCardiovascular benefitsIschemic strokeDiabetes mellitusInsulin resistanceHigher C-reactive proteinComposite of strokeHF risk scoreHigher HF riskDrug dose reductionHospitalized heart failureIncident myocardial infarctionLower mean doseC-reactive proteinBaseline patient featuresHF hospitalizationCardiovascular eventsPlacebo group
2001
Serum complement activation in congestive heart failure
Clark D, Cleman M, Pfau S, Rollins S, Ramahi T, Mayer C, Caulin-Glaser T, Daher E, Kosiborod M, Bell L, Setaro J. Serum complement activation in congestive heart failure. American Heart Journal 2001, 141: 684-690. PMID: 11275938, DOI: 10.1067/mhj.2001.113758.Peer-Reviewed Original ResearchConceptsCongestive heart failureSymptomatic heart failureC5b-9 levelsHeart failureClinical outcomesC5b-9Control patientsNew York Heart Association class IV symptomsComplement activationAge-matched control patientsClass IV symptomsCombined clinical outcomeAdverse clinical outcomesVentricular ejection fractionTerminal complement complex C5b-9Terminal complement activationComplement complex C5b-9Serum complement activationTerminal complement complexAdverse eventsCardiopulmonary bypassEjection fractionSerum levelsMyocardial injuryMyocardial infarction